DDInter1907 DDInter1819
Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic disease-modifying anti-rheumatic drug (bDMARDs) that is used in the management of various inflammatory conditions that involve the activation of IL-12 and IL-23 signalling pathways. The therapeutic use of the drug started in Canada, the US, and Europe since 2009 when it was first approved for the treatment of adult patients with moderate to severe plaque psoriasis and active psoriatic arthritis, alone or in combination with [methotrexate]. In September 2016, ustekinumab was additionally approved for the management of moderate to severe Crohn's disease
Tisagenlecleucel is a CD19-directed genetically modified autologous T cell immunotherapy, or a CAR-T cell therapy for B-cell acute lymphoblastic leukemia. It was granted approval by FDA in August 2017 under the market name Kymriah. Tisagenlecleucel is an immunocellular therapy that involves autologous T cells that are collected from each individual patient and genetically engineered to express a specific protein called a chimeric antigen receptor (CAR) that specifically target CD19 antigens. Modified T cells are infused back into the patient's body. These CD19-directed chimeric antigen receptors (CD19 CAR-T cells) direct the T cells to target and kill leukemia cells that express CD19 on the cell surface. In a multicenter clinical trial involving pediatric and young adult patients with relapsed or refractory B-cell precursor ALL, the overall remission rate within three months of treatment was 83 percent.
Ustekinumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Ustekinumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc gluconate
Ustekinumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tetracosactide
Ustekinumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Olaparib
Ustekinumab {u} may lead to a major life threatening interaction when taken with {v} Sarilumab
Ustekinumab {u} may lead to a major life threatening interaction when taken with {v} Natalizumab
Ustekinumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Ustekinumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Ustekinumab may lead to a major life threatening interaction when taken with Sarilumab
Ustekinumab may lead to a major life threatening interaction when taken with Natalizumab